francis linares oportunidad para solteros The Situation
Elemental impurities in pharmaceutical products can be introduced from a number of sources, including catalysts, raw materials, production processes, and packaging materials. The implementation of the new USP chapters <232> and <233>, and ICH Q3D guidelines on elemental impurities, in January 2018, will redefine how the pharmaceutical industry tests for elemental impurities in drug products. The quantitative determination of elemental impurities has to be conducted using appropriate procedures suitable for their intended purposes via ICP-MS / ICP-OES and will place a major emphasis on robust sample preparation.
watch The Solution
Milestone invites you to attend this Webinar, when we will present the new method requirements, define key parameters, and discuss considerations laboratories should make as they get themselves ready to implement the new methods and to consider the risk assessment on their pharmaceuticals. Through incorporating case studies, we will discuss the importance of sample preparation and the key parameters that have to be considered in order to choose the correct analytical method.
Attendees will receive the "Complete Sample Preparation Guide", the primer for QA/QC practitioners and Lab Managers with our compliments.